Effects of <em>ABCB1 rs1045642</em> polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension

Abstract

The highest antihypertensive effect in combination with the lowest incidence of adverse reactions was observed in the TT group, while patients with the CC genotype showed a low antihypertensive effect and the highest incidence of adverse effects. Patients with the CC genotype presented with adverse effects predominantly in the form of edema. A total of 33 patients reached the target blood pressure (SBP <140 mmHg; DBP <90 mmHg): two patients with the CC genotype (12%); 18 patients with the CT genotype (34%); and 13 patients with the TT genotype (43%). The intergroup differences were: CC vs CT, <i>P</i>=0.02; CC vs TT, <i>P</i>=0.02; and CT vs TT, <i>P</i>=0.05. The results of this study indicate the potential of pharmacogenetic testing for <i>rs1045642</i> SNP when prescribing amlodipine for the first time in Caucasian patients with stage I-II arterial HT.